Powered by
ANN ARBOR—Esperion Therapeutics Inc. announced a collaboration agreement with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of Nexletol and Nexlizet tablets in Japan. Both medicines were recently approved …
ANN ARBOR—The European Commission has approved the sale of new cholesterol-lowering drugs from Ann Arbor-based Esperion Therapeutics Inc. (Nasdaq: ESPR). Approved were Nilemdo, a tablet containing the new drug bempedoic …
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR) announced U.S. Food and Drug Administration approval of Nexlizet, a combination tablet of Esperion’s new non-statin cholesterol reducing drug bempedoic acid and an earlier …
ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ:ESPR) announced that the U.S. Food and Drug Administration (FDA) approved Nexletol (bempedoic acid) tablet, an oral, once-daily, non-statin cholesterol-lowering medicine. Nexletol is indicated as an …
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR) has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a “positive opinion” for both its bempedoic …
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR), the Ann Arbor-based pharmaceutical startup developing a new class of cholesterol-fighting drugs, announced that its lead drug candidate, bempedoic acid, was included in the …
ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ: ESPR), the Ann Arbor pharma startup developing a new class of cholesterol-fighting drugs, announced positive top-line results from a Phase 2 clinical study of its combination …
ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ:ESPR), the Ann Arbor-based pharmaceutical startup that’s about to introduce a new class of cholesterol-fighting drugs, reported a loss of $54.2 million or $2.01 a share …
ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ:ESPR) has provided a development update for its lead drug candidate, bempedoic acid, and financial results for the first quarter ended March 31. “The potential of …
ANN ARBOR – Esperion Therapeutics Inc. (NASDAQ:ESPR), the pharmaceutical startup developing a new cholesterol-fighting drug, reported a loss of $60 million in the fourth quarter, up from a loss of $37.9 …